Final results from the ATLAS-IT-05 study of ruxotemitide (LTX-315) in
combination with pembrolizumab to be presented at AACR 2026

Oslo, Norway, March 18, 2026: Lytix Biopharma ("Lytix" or the "Company"), a
clinical-stage immuno-oncology company developing novel intratumoral cancer
therapies, today announced that data from its Phase II ATLAS-IT-05 study
evaluating ruxotemitide (LTX-315) in combination with pembrolizumab have been
selected for presentation at the American Association for Cancer Research (AACR)
Annual Meeting 2026, taking place April 20-24, 2026 in San Diego, California. 

The presentation will highlight final results from the completed Phase II
ATLAS-IT-05 study, which evaluated intratumoral ruxotemitide in combination with
pembrolizumab in patients with unresectable advanced or metastatic melanoma who
have progressed following treatment with anti-PD-1 or anti-PD-L1 therapies.

"We are pleased that the AACR scientific committee has selected the ATLAS-IT-05
study for presentation at this year's meeting," said Øystein Rekdal, Chief
Executive Officer of Lytix Biopharma. "These results further support the
potential of ruxotemitide to induce anti-tumor immune responses in patients with
advanced melanoma who have limited treatment options following checkpoint
inhibitor therapy."

Poster Presentation Details:
> Title: Intratumoral ruxotemitide (LTX-315) in combination with pembrolizumab
in patients with unresectable advanced melanoma refractory to PD-1/PD-L1
therapy: Final results from the ATLAS-IT-05 study
> Session Title: Clinical Research - Combination Immunotherapies
> Session Date and Time: April 20, 2026